Delving into the Latest Updates on GS-9911 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

DGKA

Mechanism

DGKA inhibitors(diacylglycerol kinase alpha inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Solid tumor

Inactive Indication-

Originator Organization

Gilead Sciences, Inc.

Carna Biosciences, Inc.

Active Organization

Gilead Sciences, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors.
The primary objectives of this study are to:
* Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
* Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors

Start Date09 Oct 2023

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with GS-9911

Login to view more data

100 Translational Medicine associated with GS-9911

Login to view more data

100 Patents (Medical) associated with GS-9911

Login to view more data

100 Deals associated with GS-9911

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 1	AU	Gilead Sciences, Inc.	09 Oct 2023
Solid tumor	Phase 1	US	Gilead Sciences, Inc.	09 Oct 2023
Solid tumor	Phase 1	CA	Gilead Sciences, Inc.	09 Oct 2023